Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis

Quistrebert, J.; Hassler, S.; Bachelet, D.; Mbogning, C.; Musters, A.; Tak, P.P.; ... ; ABIRISK Consortium (2019)

Article / Letter to editor

• Rheumatoid arthritis
• Anti-drug antibodies
• Anti-TNF treatment
• Incidence
• Risk factors

• All authors: Quistrebert, J.; Hassler, S.; Bachelet, D.; Mbogning, C.; Musters, A.; Tak, P.P.; Wijbrandts, C.A.; Herenius, M.; Bergstra, S.A.; Akdemir, G.; Johannesson, M.; Combe, B.; Fautrel, B.; Chollet-Martin, S.; Gleizes, A.; Donnellan, N.; Deisenhammer, F.; Davidson, J.; Hincelin-Mery, A.; Donnes, P.; Fogdell-Hahn, A.; Vries, N. de; Huizinga, T.; Abugessaisa, I.; Saevarsdottir, S.; Hacein-Bey-Abina, S.; Pallardy, M.; Broet, P.; Mariette, X.; ABIRISK Consortium
• Date: 2019-06-30
• Journal: Seminars in Arthritis and Rheumatism
• Volume: 48
• Issue: 6
• Pages: 967 - 975
• DOI: doi:10.1016/j.semarthrit.2018.10.006